JPH058717B2 - - Google Patents

Info

Publication number
JPH058717B2
JPH058717B2 JP60171301A JP17130185A JPH058717B2 JP H058717 B2 JPH058717 B2 JP H058717B2 JP 60171301 A JP60171301 A JP 60171301A JP 17130185 A JP17130185 A JP 17130185A JP H058717 B2 JPH058717 B2 JP H058717B2
Authority
JP
Japan
Prior art keywords
propane
hydroxy
amino
disodium
diphosphonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60171301A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6143196A (ja
Inventor
Hainritsuhi Shutaaru Peetaa
Shumitsutsu Biito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHIBA GAIGII AG
HENKERU KG AUFU AKUCHEN
Original Assignee
CHIBA GAIGII AG
HENKERU KG AUFU AKUCHEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4263070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH058717(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CHIBA GAIGII AG, HENKERU KG AUFU AKUCHEN filed Critical CHIBA GAIGII AG
Publication of JPS6143196A publication Critical patent/JPS6143196A/ja
Publication of JPH058717B2 publication Critical patent/JPH058717B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP60171301A 1984-08-06 1985-08-05 新規結晶形態の３―アミノ―１―ヒドロキシ―プロパン―１，１―ジホスホン酸ジナトリウム、その製造方法並びにカルシウム及び／又はリン酸代謝障害治療剤 Granted JPS6143196A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH3768/84-0 1984-08-06
CH376884 1984-08-06

Publications (2)

Publication Number Publication Date
JPS6143196A JPS6143196A (ja) 1986-03-01
JPH058717B2 true JPH058717B2 (cg-RX-API-DMAC7.html) 1993-02-02

Family

ID=4263070

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60171301A Granted JPS6143196A (ja) 1984-08-06 1985-08-05 新規結晶形態の３―アミノ―１―ヒドロキシ―プロパン―１，１―ジホスホン酸ジナトリウム、その製造方法並びにカルシウム及び／又はリン酸代謝障害治療剤

Country Status (26)

Country Link
US (2) US4639338A (cg-RX-API-DMAC7.html)
EP (1) EP0177443B1 (cg-RX-API-DMAC7.html)
JP (1) JPS6143196A (cg-RX-API-DMAC7.html)
KR (1) KR940000817B1 (cg-RX-API-DMAC7.html)
AR (4) AR240832A1 (cg-RX-API-DMAC7.html)
AT (1) ATE47396T1 (cg-RX-API-DMAC7.html)
AU (1) AU591066B2 (cg-RX-API-DMAC7.html)
CA (1) CA1255694A (cg-RX-API-DMAC7.html)
CY (1) CY1570A (cg-RX-API-DMAC7.html)
DD (1) DD239597A5 (cg-RX-API-DMAC7.html)
DE (1) DE3573783D1 (cg-RX-API-DMAC7.html)
DK (1) DK167282B1 (cg-RX-API-DMAC7.html)
DO (1) DOP1990004769A (cg-RX-API-DMAC7.html)
ES (2) ES8701188A1 (cg-RX-API-DMAC7.html)
FI (1) FI79712C (cg-RX-API-DMAC7.html)
GR (1) GR851910B (cg-RX-API-DMAC7.html)
HK (1) HK42591A (cg-RX-API-DMAC7.html)
HU (1) HU193124B (cg-RX-API-DMAC7.html)
IE (1) IE58077B1 (cg-RX-API-DMAC7.html)
IL (1) IL75990A (cg-RX-API-DMAC7.html)
MX (1) MX9203373A (cg-RX-API-DMAC7.html)
NO (1) NO165401C (cg-RX-API-DMAC7.html)
PH (1) PH24854A (cg-RX-API-DMAC7.html)
PT (1) PT80916B (cg-RX-API-DMAC7.html)
SG (1) SG91390G (cg-RX-API-DMAC7.html)
ZA (1) ZA855892B (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH664158A5 (fr) * 1984-07-18 1988-02-15 Symphar Sa Derives propylidenediphosphonates-1,3 substitues en position 2, leur procede de preparation et compositions pharmaceutiques les contenant.
DE3770982D1 (de) * 1986-04-24 1991-08-01 Fujisawa Pharmaceutical Co Diphosphonsaeure-verbindungen, verfahren zu deren herstellung und sie enthaltende arzneimittel.
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
US4963681A (en) * 1987-07-06 1990-10-16 Norwich Eaton Pharmaceuticals, Inc. Process for synthesis of aminomethylene phosphonoalkylphosphinates
IT1222734B (it) * 1987-09-25 1990-09-12 Scalvo S P A Formulaziopne farmaceutiche e forme di dosaggio per la somminaistarzione rettale di calcitonina
PH26923A (en) * 1989-03-08 1992-12-03 Ciba Geigy N-substituted amino alkanediphosphonic acids
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
TW237386B (cg-RX-API-DMAC7.html) 1992-04-15 1995-01-01 Ciba Geigy
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
JP3266395B2 (ja) * 1993-11-24 2002-03-18 富士写真フイルム株式会社 有機薬品の晶析方法
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
ATE280173T1 (de) * 1997-07-15 2004-11-15 Gador Sa Kristalline form von n,n-dimethyl-3-amino-1- hydroxypropan-1,1-diphosphonsäure mononatriumsalz monohydrat und ein verfahren zu ihrer herstellung
RO122854B1 (ro) 1998-08-27 2010-03-30 Teva Pharmaceutical Industries Ltd. Alendronat de sodiu hidrat, procedeu de obţinere şi compoziţie farmaceutică
EP1702924A3 (en) * 1998-08-27 2007-07-18 Teva Pharmaceutical Industries Ltd Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6794536B1 (en) * 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
CA2353942A1 (en) * 1998-12-10 2000-06-15 Edward C. Shinal Method for preparation of disodium pamidronate
US6143919A (en) * 1999-05-18 2000-11-07 3M Innovative Properties Company Polymerizable acidic compounds and methods of preparation
US6315566B1 (en) 1999-05-18 2001-11-13 3M Innovative Properties Company Dental materials
US6963008B2 (en) * 1999-07-19 2005-11-08 Teva Pharmaceutical Industries Ltd. Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
ES2153794B1 (es) * 1999-08-06 2001-10-16 Medichem Sa Procedimiento para la obtencion del acido 4-amino-1-hidroxibutiliden-1,1-bisfosfonico y de su sal monosodica trihidratada.
KR100343232B1 (ko) * 1999-12-10 2002-07-10 김재윤 결정성 파미드론산 이나트륨염 수화물과 그의 제조방법
EP1671638A1 (en) * 2000-09-18 2006-06-21 F H Faulding & Co. Limited Disphosphonate solutions
BRPI0116865B8 (pt) * 2001-01-23 2021-05-25 Gador Sa composição compreendendo bisfosfonatos para prevenção e/ou tratamento de doenças metabólicas dos ossos, processo para preparar tal composição e uso desta
BR0209361A (pt) 2001-05-02 2004-06-08 Sicor Inc Dissódio de pamidronato injetável
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
ITMI20012751A1 (it) * 2001-12-21 2003-06-21 Lyogen Ltd Sale monosodico dell'acido pamidronico e procedimento per la sua preparazione
WO2003057136A2 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
PL212072B1 (pl) * 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
WO2005054260A1 (en) * 2003-12-04 2005-06-16 Mustafa Nevzat Ilac Sanayii A.S. Method for producing pure disodium pamidronate
WO2005115331A2 (en) 2004-05-24 2005-12-08 The Procter & Gamble Company Enteric solid oral dosage form of bisphosphonate containing a chelating agent
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
CA2646334A1 (en) * 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
WO2008116133A1 (en) * 2007-03-21 2008-09-25 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
PL2473172T3 (pl) 2009-09-01 2015-08-31 Univ Duke Kompozycje bisfosfonianowe i sposoby do leczenia niewydolności serca
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
EP2558106A1 (en) 2010-04-16 2013-02-20 Novartis AG Methods and compositions for improving implant osseointegration
CN104010647A (zh) 2011-11-16 2014-08-27 杜克大学 用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
CN109331027A (zh) * 2012-05-14 2019-02-15 安泰赛普生物风投二代有限责任公司 用于减轻炎性疼痛或相关病症的包含唑来膦酸或相关化合物的组合物
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
KR101995432B1 (ko) * 2016-10-13 2019-07-02 엘지전자 주식회사 공기조화기 및 그 제어방법
EP3553067A1 (en) * 2018-04-10 2019-10-16 Abiogen Pharma S.p.A. Polymorph of sodium neridronate and preparation process thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2130794C3 (de) * 1971-06-22 1974-07-11 Joh. A. Benckiser Gmbh, 6700 Ludwigshafen Verfahren zur Herstellung von l-Hydroxy-S-amino-propan-ljl-diphosphonsäure
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4134969A (en) * 1974-02-04 1979-01-16 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2553963A1 (de) * 1975-12-01 1977-06-08 Henkel & Cie Gmbh Pharmazeutische praeparate zur behandlung von stoerungen des calciumstoffwechsels
DK506476A (da) * 1975-12-01 1977-06-02 Henkel & Cie Gmbh Farmaceutiske preparater til behandling af calciumstofs skifteforstyrrelser
JPS5283957A (en) * 1975-12-01 1977-07-13 Henkel & Cie Gmbh Medicine for treating metabolic obstruction of calcium
SE409706B (sv) * 1976-05-21 1979-09-03 Astra Pharma Prod Forfarande for framstellning av n,n-dimetyl-3-(4-bromfenyl)-3-3(3-pyridyl)-allylamin dihydroklorid monohydrat
DE2702631A1 (de) * 1977-01-22 1978-07-27 Henkel Kgaa Verfahren zur herstellung von 1-hydroxy-3-amino-propan-1,1-diphosphonsaeuren
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4304734A (en) * 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
DE3151038A1 (de) * 1981-12-23 1983-07-28 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von 3-amino-1-hydroxypropan-1,1-diphosphonsaeure
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
CH664158A5 (fr) * 1984-07-18 1988-02-15 Symphar Sa Derives propylidenediphosphonates-1,3 substitues en position 2, leur procede de preparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
AU4577785A (en) 1986-02-13
NO165401C (no) 1991-02-06
PT80916A (en) 1985-09-01
DOP1990004769A (es) 1999-08-19
HK42591A (en) 1991-06-07
HU193124B (en) 1987-08-28
JPS6143196A (ja) 1986-03-01
ATE47396T1 (de) 1989-11-15
ES8706707A1 (es) 1987-07-01
DE3573783D1 (en) 1989-11-23
KR940000817B1 (ko) 1994-02-02
EP0177443B1 (de) 1989-10-18
ES555602A0 (es) 1987-07-01
FI852986L (fi) 1986-02-07
DD239597A5 (de) 1986-10-01
PH24854A (en) 1990-12-26
FI79712C (fi) 1990-02-12
GR851910B (cg-RX-API-DMAC7.html) 1985-12-03
IL75990A (en) 1989-07-31
US4639338A (en) 1987-01-27
NO853087L (no) 1986-02-07
ZA855892B (en) 1986-03-26
IE58077B1 (en) 1993-06-30
AU591066B2 (en) 1989-11-30
EP0177443A1 (de) 1986-04-09
FI79712B (fi) 1989-10-31
DK355485D0 (da) 1985-08-05
AR240832A1 (es) 1991-02-28
FI852986A0 (fi) 1985-08-02
DK167282B1 (da) 1993-10-04
ES8701188A1 (es) 1986-11-16
MX9203373A (es) 1992-09-01
CY1570A (en) 1991-12-20
PT80916B (pt) 1987-12-30
AR244697A1 (es) 1993-11-30
DK355485A (da) 1986-02-07
IE851931L (en) 1986-02-06
AR244698A1 (es) 1993-11-30
KR860001821A (ko) 1986-03-22
CA1255694A (en) 1989-06-13
NO165401B (no) 1990-10-29
ES545899A0 (es) 1986-11-16
AR244696A1 (es) 1993-11-30
US4711880A (en) 1987-12-08
SG91390G (en) 1991-01-18
HUT38361A (en) 1986-05-28
AR240832A2 (es) 1991-02-28

Similar Documents

Publication Publication Date Title
JPH058717B2 (cg-RX-API-DMAC7.html)
JP4104687B2 (ja) Ｃｄｃｈの新規な結晶変態、その製造法及びこの変態を含む製薬学的調剤
CS272241B2 (en) Method of crystalline citromycindihydrate production
CA2463815C (en) Pharmaceutically acceptable alendronate salts in amorphous form
HU227589B1 (en) Crystal form of (s)-omeprazole
CZ281318B6 (cs) Monohydrát mometasonfuroátu, způsob přípravy této látky a přípravy lékových kompozic z ní
JP3090960B2 (ja) クレアチン―ピルベート及びその製造方法
KR101153606B1 (ko) 아타자나비르 비술페이트 및 신규 형태의 제조 방법
JPH0324010A (ja) Ｌ―カルニチン―マグネシウム―クエン酸塩
HU228008B1 (en) Stable,non-hygroscopic salts of l(-)carnitine and alkanoyl l(-) carnitines,a process for their preparation and solid,orally administrable compositions containing such salts
AU2019350699A1 (en) Process of making calcium alpha-ketoglutarate
RU2088584C1 (ru) Кристаллический полугидрат 4-(5,6,7,8-тетрагидроимидазо [1,5-а]пиридин-5-ил)-бензонитрил-гидрохлорида
WO2010131035A1 (en) Novel crystalline polymorph of sitagliptin dihydrogen phosphate
EP1375497B1 (en) Magnesium salt of s-omeprazole
EP1453791A1 (en) Acetyl l-carnitine salt with a dicarboxilic organic acid and process for preparing same
JP2560073B2 (ja) 乳酸カルシウムーグリセロール付加物およびその製法
JPH0157115B2 (cg-RX-API-DMAC7.html)
US3644395A (en) Phenylbutazone-sodium-monoglycerate
NO171111B (no) Fremgangsmaate til fremstilling av en ny krystallmodifikasjon av dinatrium-3-amino-1-hydroksypropan-1,1-difosfonat
WO2025120626A2 (en) Synthetic method
JPH10503532A (ja) レソピトロン二塩酸塩の新規多形およびその水和形その製造方法およびそれを含有する組成物
HU179752B (hu) Eljárás S-metil-metionin-szulfóniumkloríd előállítására
CZ280394B6 (cs) Vícejaderné komplexní sloučeniny horčíku s aminodikarbonovými kyselinami, halogenem a způsob jejich přípravy a použití
HU210609A9 (hu) Kalcium-laktát/glicerin adduktum és eljárás előállítására
JPS6141332B2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term